References
- Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin. Chest Med.30(4), 701–716 (2009).
- Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur. Respir. J.38(6), 1398–1405 (2011).
- Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host–pathogen interaction. FEMS Microbiol. Rev.35(6), 1126–1157 (2011).
- Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr. Res.338(23), 2539–2547 (2003).
- Demkow U, Filewska M, Michalowska-Mitczuk D et al. Heterogeneity of antibody response to myobacterial antigens in different clinical manifestations of pulmonary tuberculosis. J. Physiol. Pharmacol.58(Suppl. 5 Pt 1), 117–127 (2007).
- Tessema TA, Bjune G, Hamasur B, Svenson S, Syre H, Bjorvatn B. Circulating antibodies to lipoarabinomannan in relation to sputum microscopy, clinical features and urinary anti-lipoarabinomannan detection in pulmonary tuberculosis. Scand. J. Infect. Dis.34(2), 97–103 (2002).
- Arias-Bouda LMP, Kuijper S, Van der Werf A, Nguyen LN, Jansen HM, Kolk AHJ. Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis. Clin. Diagn. Lab. Immunol.10(4), 702–709 (2003).
- WHO. WHO (2011) Policy Statement: Commercial Serodiagnostic Tests for Diagnosis of Tuberculosis. WHO, Geneva, Switzerland (2011).
- Hamasur B, Bruchfeld J, Haile M et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. J. Microbiol. Methods45(1), 41–52 (2001).
- Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect. Immun.68(1), 335–341 (2000).
- Bhattacharya A, Ranadive SN, Kale M, Battacharya S. Antibody-based enzyme-linked immunosorbent assay for determination of immune complexes in clinical tuberculosis. Am. Rev. Respir. Dis.134, 205–209 (1986).
- Roberts-Thomsom PJ, Shepherd K. Molecular size heterogeneity of immunoglobulins in health and disease. Clin. Exp. Immunol.79, 328–334 (1990).
- Wood R, Racow K, Bekker L-G et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria. BMC Infect. Dis.12(1), 47 (2012).
- Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whielaw A, Wood R. Characteristics and early outcomes with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin. Infect. Dis.54(8), 1071–1079 (2012).
- Boehme CC, Nabeta P, Hilleman D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med.363, 1005–1015 (2010).
- Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications and informationreasources. Inst. Lab. Anim. Res. J.46, 943–954 (2005).
- Ritter MA. Polyclonal and monoclonal antibodies. Methods Mol. Med.40, 23–34 (2000).
- Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect. Dis.9, 173–184 (2009).
- Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker L-G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS23(14), 1875–1880 (2009).
- Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect. Dis.12(3), 383–392 (2012).